Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care
|
|
- Melissa Hunt
- 5 years ago
- Views:
Transcription
1 Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care May 1, 2013 Anaheim, California Educational Partner:
2 Session 5: Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care Learning Objectives 1. Diagnose irritable bowel syndrome (IBS) based on symptoms that may be shared with other functional gastrointestinal disorders or organic diseases. 2. Compare and contrast the efficacy and safety of available pharmacologic and nonpharmacologic treatment options for IBS. 3. Apply appropriate and comprehensive treatment strategies to enhance the care of patients with IBS. Faculty Lawrence R. Schiller, MD, FACS Professor of Internal Medicine Texas A&M Health Science Center, Dallas Campus Program Director Gastroenterology Fellowship Baylor University Medical Center Dallas, Texas Lawrence R. Schiller, MD, FACS, was born in Philadelphia and attended Pennsylvania State University and Jefferson Medical College of Philadelphia. He completed his internal medicine training at Temple University Hospital, also in Philadelphia, and then served 2 years in the U.S. Army Medical Corps. Dr Schiller moved to Texas in 1978 for gastroenterology training at the University of Texas (UT) Southwestern Medical Center, where he remained on the faculty at the medical school; he also spent 5 years as an attending physician at the Dallas VA Hospital. In 1985, Dr Schiller moved to Baylor University Medical Center to continue research activities with Dr John Fordtran, and has been there ever since, most recently serving as program director for the Gastroenterology Fellowship. Dr Schiller has been involved in patient care as a founding partner of Digestive Health Associates of Texas, one of the largest single-specialty gastroenterology practices in the United States, and has continued with research and education activities at Baylor and UT Southwestern. He is currently an attending physician and chairman of the Institutional Review Board for Human Subject Protection at Baylor, as well as clinical professor of internal medicine at UT Southwestern, where he has won 2 fellow teaching awards. Dr Schiller has been elected to fellowships in the American College of Physicians and the American College of Gastroenterology (ACG) and has served as ACG governor of the North Texas region. Currently serving as ACG president, he has also served as president of the Texas Society for Gastroenterology and Endoscopy. Dr Schiller has published more than 80 papers and 45 book chapters dealing with gastric physiology, intestinal transport, diarrheal diseases, and motility disorders. Brian E. Lacy, MD, PhD Professor of Medicine Geisel School of Medicine at Dartmouth College Hanover, New Hampshire Director, Gastrointestinal Motility Laboratory Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire Brian E. Lacy, MD, PhD, is currently professor of medicine at the Geisel School of Medicine at Dartmouth College in Hanover, New Hampshire. He is also section chief of the Division of Gastroenterology and Hepatology, and director of the Gastrointestinal Motility Laboratory at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. Dr Lacy s clinical and basic science research interests focus on disorders of gastrointestinal (GI) motility, with an emphasis on IBS, dyspepsia, gastroparesis, acid reflux disease, constipation, intestinal pseudo-obstruction, achalasia, and visceral pain. He is Session 5
3 the author or coauthor of more than 85 peer-reviewed articles, the author or coauthor of numerous textbook chapters on GI motility disorders and functional bowel disorders, and a reviewer for a number of scientific journals. Dr Lacy is coauthor of Healing Heartburn, a book for the general public on acid reflux disease; is the author of Making Sense of IBS, a book for the general public on irritable bowel syndrome; and is the editor and author of Curbside Consultations in IBS: 49 Clinical Questions. Dr Lacy is a member of the American College of Gastroenterology, the American Gastroenterology Association, the American Motility Society, and the Rome Committee. Dr Lacy earned his doctorate in cell biology from Georgetown University in Washington, DC, and his medical degree from the University of Maryland in Baltimore. He completed a residency in internal medicine at Dartmouth-Hitchcock, where he continued his training as chief resident and then as a fellow in gastroenterology. He is board-certified in gastroenterology. Faculty Financial Disclosure Statements The presenting faculty reported the following: Dr Schiller is a speaker for Ironwood Pharmaceuticals, Inc.; Forest Laboratories, Inc.; and Takeda Pharmaceutical Company Limited; and consultant for Synergy Pharmaceuticals, Inc. Dr Lacy serves as scientific advisory board member for Ironwood Pharmaceuticals, Inc.; Salix Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited. Education Partner Financial Disclosure Statement The content collaborators at CME Incite have reported the following: Rose O Connor, PhD, and Monique Pond, PhD, have no financial relationships to disclose. Suggested Reading List Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011;106(3): ; quiz 515. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al; American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl 1):S1-S35. Cash BD, Chang E, Talley NJ, et al. Fresh perspectives in chronic constipation and other functional bowel disorders. Rev Gastroenterol Disord. 2007;7(3): Ford AC, Talley NJ. IBS in 2010: advances in pathophysiology, diagnosis and treatment. Nat Rev Gastroenterol Hepatol. 2011;8(2): Halpert A, Dalton CB, Palsson O, et al. What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ). Am J Gastroenterol. 2007;102(9): Hasler WL. Traditional thoughts on the pathophysiology of irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40(1): Johannesson E, Simrén M, Strid H, et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5): Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139(6): Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5): Pimentel M, Lembo A, Chey WD, et al; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1): Session 5
4 SESSION 5 2:45 PM 4:00 PM Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care SPEAKERS Lawrence R. Schiller, MD, FACS Brian E. Lacy, MD, PhD Presenter Disclosure Information The following relationships exist related to this presentation: Dr Schiller is a speaker for Ironwood Pharmaceuticals, Inc.; Forest Laboratories, Inc.; and Takeda Pharmaceutical Company Limited; and consultant for Synergy Pharmaceuticals, Inc. Dr Lacy serves as scientific advisory board member for Ironwood Pharmaceuticals, Inc.; Salix Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited. Off-Label/Investigational Discussion In accordance with pmicme policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. Lawrence R. Schiller, MD, FACG Digestive Health Associates of Texas Baylor University Medical Center Dallas, Texas Brian E. Lacy, MD, PhD Professor of Medicine Dartmouth Medical School Hanover, New Hampshire Director of the GI Motility Laboratory Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire Diagnose IBS based on symptoms that may be shared with other functional GI disorders or organic diseases Compare and contrast the efficacy and safety of available pharmacologic and nonpharmacologic treatment options for IBS Apply appropriate and comprehensive treatment strategies to enhance the management of patients with IBS IBS, irritable bowel syndrome; GI, gastrointestinal. A3309 Alosetron Amitriptyline Atropine Cholestyramine Citalopram Desipramine Diphenoxylate Doxepin Fluoxetine Hyoscyamine Imipramine Linaclotide Loperamide Lubiprostone Paroxetine Prucalopride Psyllium Rifaximin No trade name Lotronex Elavil, Tryptizol, Laroxyl, etc Sal-tropine Questran Celexa Norpramin, Pertofane Lomotil, Lonox, Dimotal, etc Adapin, Silenor, Sinequan, etc Prozac, Sarafem, Fontex, etc A-Spas, Anapaz, Cytospaz, etc Antideprin, Deprimin, Deprinol, etc Linzess Imodium, Diar-Aid, Diamode, etc Amitiza Paxil, Aropax, Seroxat, Pexeva, etc Resolor Fiberall, Benefiber, Metamucil, etc Xifaxan 1. None 2. 1 to to to to to to >60 1
5 A 43-year-old patient presents with IBS symptoms for >3 months prior to initial visit without the presence of alarm features. What should be your next course of action 1. Watch and wait for emergence of alarm features 2. Perform routine lab tests (CBC, CMP, TSH, stool O+P, abdominal imaging) 3. Refer for colonoscopy 4. Begin treatment for IBS immediately 5. Unsure How would you distinguish IBS from other functional GI disorders, such as functional constipation (FC) or functional diarrhea (FD) 1. Pain is more prominent than bowel disturbance in FC or FD 2. Pain is more prominent than bowel disturbance in IBS 3. Frequency of bowel habits differs between FC/FD and IBS 4. Changes in diet have more impact on patients with IBS than on patients with FC or FD 5. Unsure CBC, complete blood count; CMP, comprehensive metabolic panel; TSH, thyroid-stimulating hormone, O+P, ova and parasites. Which of the following therapies is an evidencebased treatment option for patients with IBS-C 1. Hyoscyamine 2. Lubiprostone 3. Loperamide 4. Alosetron 5. Unsure What medication would you recommend for a 57-year-old woman with severe IBS-D who has previously tried anticholinergics, loperamide, SSRIs, and dietary changes, but still has abdominal pain and urgency 1. Diphenoxylate with atropine 2. Lubiprostone 3. Polyethylene glycol 4. Alosetron 5. Any of the above 6. Unsure IBS-C, IBS Constipation. IBS-D, IBS Diarrhea; SSRIs, selective serotonin reuptake inhibitors; PEG, polyethylene glycol. Which of the following mechanistic effects is thought to be influenced by the use of probiotics 1. Immune function 2. Anti-inflammatory effects 3. Alteration of local ph 4. All of the above 5. Unsure 2
6 AC, a 45-year-old woman, presents with a 6-year history of abdominal pain and variable bowel habits Crampy pain is located in left lower quadrant Pain peaks just before bowel movement Pain is relieved by defecation Bowel movements vary in consistency from loose to hard Frequency of bowel movements varies from once weekly to 4 times per day Other symptoms include indigestion, early satiety, bloating, excessive flatulence, and belching Patient has experienced no weight loss or rectal bleeding Previous evaluation included colonoscopy with biopsies (negative), endoscopy with biopsies (negative), and abdominal sonogram (negative) Patient has tried lactose-free diet, increased dietary fiber, dicyclomine, and hyoscyamine, all without benefit Physical examination is unremarkable 1. Past surgical history 2. History of migraine headaches 3. Discussion of life stressors and relation to symptoms 4. Discussion of physical and sexual abuse 5. Family history of digestive symptoms 1. Laboratory tests: CBC, CMP, TSH 2. Pelvic examination 3. Diet and symptom diary for 2 weeks 4. CT scan of abdomen/pelvis 5. Repeat colonoscopy and endoscopy Lawrence R. Schiller, MD, FACG Worldwide prevalence: 7% to 10% 1.5 times more prevalent in women More commonly diagnosed in patients <50 years of age More common in lower socioeconomic groups Patients with IBS have more physician visits, more hospitalizations, more missed workdays, more prescriptions, and more diagnostic tests than those without the disorder American College of Gastroenterology Task Force on Irritable Bowel Syndrome; Brandt LJ, et al. Am J Gastroenterol. 2009;104(suppl 1):S1-S35. 3
7 IBS is a syndrome a collection of symptoms Diagnosis is possible by taking a thorough history of symptoms Since symptoms may be due to other disorders, the provider must consider alternative organic diagnoses Serious organic illnesses typically produce alarm symptoms Abdominal pain Anywhere in abdomen Characteristically relieved by defecation Altered stool frequency Excess frequency: >2 bowel movements/day Infrequency: <3 bowel movements/week Altered stool form Loose to lumpy Hard or Lumpy Stools (%) IBS-C IBS-U IBS-M IBS-D Loose or Watery Stools (%) IBS-C: Constipation-predominant IBS IBS-D: Diarrhea-predominant IBS IBS-M: Mixed IBS (hard and loose stools over periods of weeks and months) IBS-U: Unsubtyped IBS Recurrent abdominal pain or discomfort at least 3 days/month in the last 3 months associated with 2 of the following: Improvement with defecation Onset associated with a change in frequency of stool Onset associated with a change in form of stool Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis Additional IBS testing, including routine laboratory tests and colonoscopy, unnecessary unless alarm features present Longstreth GF, et al. Gastroenterology. 2006;130(5): ; erratum in: Gastroenterology. 2006;131(2):688. Longstreth GF, et al. Gastroenterology. 2006;130(5): ; erratum in: Gastroenterology. 2006;131(2):688. Refractory or worsening abdominal symptoms Older patient ( 50 years of age; 45 years of age if African American) Blood in stools Anemia Weight loss (unintentional) Anorexia Family history of organic GI disease Further investigation warranted Consider colonoscopy Routine laboratory tests (CBC, CMP) and TSH, stool O+P, abdominal imaging not recommended Serologic testing for celiac disease (IBS-D/M) recommended Lactose breath testing selected cases Colonoscopy recommended if >50 years of age, with biopsies in refractory IBS-D (to exclude microscopic colitis) ACG, American College of Gastroenterology. Lembo A, Camilleri M. N Engl J Med. 2003;349(14): ; Brandt LJ, et al. Am J Gastroenterol. 2005;100(suppl 1):S5- S21; Cash BD, et al. Rev Gastroenterol Disord. 2007;7(3): American College of Gastroenterology Task Force on Irritable Bowel Syndrome; Brandt LJ, et al. Am J Gastroenterol. 2009;104(suppl 1):S1-S35. 4
8 Dysmotility Hypersensitivity Disordered brain processing Enteric nervous system dysfunction SERT activity Postinfectious IBS Somatization syndrome Small intestinal bacterial overgrowth Mast cell dysfunction Dysbiosis Food intolerances Food allergy Genetics SERT, serotonin transporter. Hasler WL. Gastroenterol Clin North Am. 2011;40(1):21-43; Ford AC, Talley NJ. Nat Rev Gastroenterol Hepatol. 2011;8(2): Other functional GI disorders Functional constipation, functional diarrhea Pain less prominent than bowel disturbance Functional abdominal pain Bowel disturbance less prominent Gastrointestinal Colorectal cancer Diverticular disease Gynecologic Ovarian cancer Endometriosis Drugs Opiates Anticholinergics Antidepressants Metabolic/endocrine Hypothyroidism Diabetes Neurologic Parkinson s disease Multiple sclerosis Autonomic neuropathy Other Amyloidosis Scleroderma Candelli M, et al. Hepatogastroenterology. 2001;48(40): ; Locke GR III, et al. Gastroenterology. 2000;119(6): Dietary factors Lactose Gluten Other FODMAPs Drugs Infection Giardiasis Amebiasis Malabsorption Celiac disease FODMAPs, fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. Inflammatory bowel disease Crohn s disease Ulcerative colitis Microscopic colitis Psychological Panic disorder Somatization Depression Candelli M, et al. Hepatogastroenterology. 2001;48(40): ; Locke GR III, et al. Gastroenterology. 2000;119(6): Identify IBS symptoms, presence of alarm features Meets criteria, no alarm features make diagnosis of IBS Doesn t meet criteria, has alarm features look for alternative diagnosis Symptomatic treatment for predominant symptoms Good response continue Rx Assess response to treatment Poor response reassess Longstreth GF, et al. Gastroenterology. 2006;130(5): ; erratum in: Gastroenterology. 2006;131(2):688; American College of Gastroenterology Task Force on Irritable Bowel Syndrome; Brandt LJ, et al. Am J Gastroenterol. 2009;104(suppl 1):S1-S35. 5
9 A 43-year-old patient presents with IBS symptoms for >3 months prior to initial visit without the presence of alarm features. What should be your next course of action 1. Watch and wait for emergence of alarm features 2. Perform routine lab tests (CBC, CMP, TSH, stool O+P, abdominal imaging) 3. Refer for colonoscopy 4. Begin treatment for IBS immediately 5. None of the above 6. Unsure How would you distinguish IBS from other functional GI disorders, such as functional constipation (FC) or functional diarrhea (FD) 1. Pain is more prominent than bowel disturbance in FC or FD 2. Pain is more prominent than bowel disturbance in IBS 3. Frequency of bowel habits differs between FC/FD and IBS 4. Changes in diet have more impact on patients with IBS than on patients with FC or FD 5. Unsure Brian E. Lacy, MD, PhD Psychological treatments Goal: improved function Continuing care + Follow-up visit Manage stress Drug therapy + Diet, lifestyle advice Positive diagnosis Explain, reassure Severe (25%) Moderate (35%) Mild (40%) Francis CY, Morris J, Whorwell PJ. Aliment Pharmacol Ther. 1997;11: Drossman DA, et al. Am J Gastroenterol. 2011;106: Lifestyle 1 Survey of 1242 patients: following interventions improved symptoms Small meals (69%), avoiding fat (64%), increasing fiber (58%), avoiding milk products (54%) Food allergy 2 limited evidence Lactose 3 higher % of lactose maldigestion Gluten 4,5 studies indicate possible link Fructose intolerance 6 studies indicate possible link Treatment Modality Studies, N 1. Halpert A, et al. Am J Gastroenterol. 2007;102: Locke GR 3 rd, et al. Am J Gastroenterol. 2200;95: *Total GI symptom severity measured at 1 year compared to baseline values in gut-directed hypnotherapy group. 3. Brandt LJ, et al. Am J Gastroenterol. 2009;104(suppl 1):S1-S Wahnschaffe U, et al. Clin Gastroenterol Hepatol. 2007;5: Biesiekierski JR, et al. Am J Gastroenterol. 2011;106: Shepherd SJ, et al. J Am Diet Assoc. 2006;106: Ford AC, et al. Gut. 2009;58: Lindfors P, et al. Am J Gastroenterol. 2012;107: Pts N C RR (95% CI) Cognitive behavioral therapy (CBT) ( ) Multicomponent psychological therapy ( ) Stress management ( ) Dynamic psychotherapy ( ) Hypnotherapy P<0.01* 6
10 Abdominal pain/discomfort Antispasmodics* Antidepressants* TCAs/SSRIs Alosetron (5HT-3 antagonist) Lubiprostone (chloride channel activator) Linaclotide (guanylate cyclase-c agonist) Abdominal pain/ discomfort Bloating/ distension Bloating Rifaximin* Probiotics Constipation Fiber* MOM/PEG solution* Lubiprostone (chloride channel activator) Linaclotide (guanylate cyclase-c agonist) Altered bowel function *These agents are not currently FDA-approved for IBS. TCAs, tricyclic antidepressants. Diarrhea Loperamide* Diphenoxylateatropine* Cholestyramine* Alosetron Rifaximin* Brandt LJ, et al. Am J Gastroenterol. 2002;97(11 suppl):s7-s26. Drossman DA, et al. Gastroenterology. 2002;123: Randomized, placebo-controlled trial (N=275 patients with IBS) Primary endpoint: adequate symptom relief 2 weeks in previous month, analyzed after 1, 2, and 3 months RESULT Higher % responders in psyllium vs placebo group during first month (57% vs 35%) Higher % responders through 2 months of treatment (59% vs 41%) No significant improvement was noted in measurement of abdominal pain relief No adult studies of laxatives in IBS-C 1 27 adolescents: PEG improved number of bowel movements (P<0.05) but not pain in IBS-C patients #BMs Pain Level Pre- Treatment Post- Treatment Bijkerk CJ, et al. BMJ. 2009;339: Brandt L, et al. Am J Gastroenterol. 2009;104(suppl):S1-S Khoshoo V, et al. Aliment Pharmacol Ther. 2006;23: Phase 3 12-week randomized controlled trials Results: patients receiving lubiprostone (8 μg BID) twice as likely to achieve overall response 7.8% difference (P=0.001) vs placebo % Placebo n= % Lubiprostone n=783 Ensure absence of mechanical obstruction before beginning therapy Drossman DA, et al. Aliment Pharmacol Ther. 2009;29: Responder (%) % Responders FDA Primary Endpoint ( 6/12 Weeks) Placebo (n=403) *P< for all analyses of linaclotide vs placebo groups, using Cochran-Mantel-Haenszel test Chey WD, et al. Am J Gastroenterol. 2012; epub September 18. Linaclotide 290 μg (n=401) FDA Primary Endpoint: 30% reduction worst abdominal pain and increase 1 CSBM, both for 6/12 weeks 7
11 % Change in Worst Abdominal Pain Linaclotide 290 µg Placebo -60 BL Trial Week N=804 ITT population, observed cases, LS-means presented: P-values based on ANCOVA P= for Week 1 P< for Weeks 2-26 at each week. Bars represent 95% CI. Diarrhea is the most common adverse event associated with linaclotide treatment; other AEs were comparable between placebo and linaclotide treatment groups. Chey WD, et al. Am J Gastroenterol. 2012; epub September 18. Low doses 2 mg once or twice daily may be effective to decrease stool frequency, improve stool consistency 2 randomized controlled trials in IBS (N=42) show efficacy for diarrhea No impact on symptoms of abdominal discomfort, bloating, or global IBS Adverse effects: dizziness, abdominal pain/bloat, constipation, dry mouth, fatigue Study N Female, % Response: Alosetron, % Response: Placebo, % Therapeutic Gain, % Camilleri Camilleri Camilleri Lembo Jones 5 * *Comparison mebeverine instead of placebo. Mebeverine not available in the US. Accessed May 15, Camilleri M, et al. Aliment Pharmacol Ther. 1999;13: Camilleri M, et al. Lancet. 2000;355: Camilleri M, et al. Arch Intern Med. 2001;161: Lembo T, et al. Am J Gastroenterol. 2001;96: Jones R, et al. Aliment Pharmacol Ther. 1999;13: Female patients with chronic, severe IBS-D who failed other treatments Dose: mg QD to BID Patient education regarding possible serious adverse effects of severe constipation or ischemic colitis 0.95 cases of ischemic colitis/1000 patient-years 0.36 cases of severe constipation/1000 patient-years Ischemic colitis usually occurs within the first month of therapy if it occurs Prescribing program mandated by FDA Requires patient to sign attestation form Lactobacilli anerobic, gram (+) rods casei plantarum acidophilus reuteri Bifidobacteria anerobic, gram (+) rods VSL #3 (8 separate organisms: 3 Bifidobacteria, 1 Streptococcus, 4 Lactobacilli) Enterococcus Streptococcus salivarius Saccharomyces Accessed May 15, Moayyedi P, et al. Gut. 2010:59: Epub 2008 Dec 17. 8
12 Competitive inhibition Barrier protection Immune effects Anti-inflammatory effects Production of various substances (enzymes, SCFA, bacteriocidal agents) Ability to alter local ph and physiology Provides nutrition to colonocytes Answering Yes at Week 4 (%) P= B Infantis B Infantis B Infantis Placebo 1 x x x 10 6 SGA (Subjects Global Assessment) a yes/no response to the following question: Please consider how you felt in the past week in regard to your IBS, in particular your general well being, and symptoms of abdominal discomfort or pain, bloating or distension, and altered bowel habit. Compared with the way you felt before beginning the medication, have you had adequate relief of your IBS symptoms Camilleri M. J Clin Gastroenterol. 2006;40: Whorwell PJ, et al. Am J Gastroenterol. 2006;101: randomized controlled trials comparing 12 different antispasmodics vs placebo (N=1778 patients) Significant heterogeneity among studies Many agents not available in US Appear most useful for abdominal pain In meta-analysis, symptoms persist in 39% of patients receiving antispasmodics vs 56% of placebo-treated patients (RR: 0.68; 95% CI: ) Ford AC, et al. BMJ. 2008;337:a2313. TCAs: 9 studies (N=319 drug vs 256 control) Imipramine, desipramine, amitriptyline, doxepin*; doses mg Meta-analysis favors treatment SSRIs: 5 studies (N=113 drug vs 117 control) Fluoxetine, paroxetine, citalopram*; dose mg Meta-analysis favors treatment *These agents are not currently FDA-approved for IBS. Ford AC, et al. Gut. 2009;58:
13 2 Phase 3 randomized controlled trials; N=1260 patients Rifaximin 550 mg TID x 2 weeks; patients followed additional 10 weeks 40.7% vs 31.7% with adequate relief of global symptoms (P<0.001) T-I T-II Comb Rifaximin Placebo Not systemically absorbed Doses studied for IBS: 400 mg BID to 550 mg TID Primary adverse effects include headache, abdominal pain, and upper respiratory tract infection T-I, TARGET 1 trial; T-II, TARGET 2 trial; Comb, Combination of both trials. *Rifaximin is not currently FDA-approved for IBS. Pimentel M, et al. N Engl J Med. 2011;364: Ford AC, et al. Clin Gastroenterol Hepatol. 2009;7: Pimentel M, et al. N Engl J Med. 2011;364: Treatment depends on severity of IBS symptoms Management of diet, exercise, and sleep build foundation for success of other therapies Limited evidence but useful starting points Pharmacologic therapies directed at predominant symptoms Evidence-based treatments include IBS-C: lubiprostone, linaclotide, SSRIs IBS-D: alosetron, TCAs Probiotics may help with bloating Centrally acting therapies (eg, antidepressants) in select patients may help with improving general well being Novel agents in development Rifaximin is a promising therapy for IBS-D Which of the following therapies is an evidencebased treatment option for patients with IBS-C 1. Hyoscyamine 2. Lubiprostone 3. Loperamide 4. Alosetron 5. Unsure What medication would you recommend for a 57-year-old woman with severe IBS-D who has previously tried anticholinergics, loperamide, SSRIs, and dietary changes, but still has abdominal pain and urgency 1. Diphenoxylate with atropine 2. Lubiprostone 3. Polyethylene glycol 4. Alosetron 5. Any of the above 6. Unsure Which of the following mechanistic effects is thought to be influenced by the use of probiotics 1. Immune function 2. Anti-inflammatory effects 3. Alteration of local ph 4. All of the above 5. Unsure 10
14 Jenny, a 27-year-old waitress, presents for a second opinion 6-year history of lower abdominal pain, cramps, and urgent diarrhea Occasional episodes of urgent incontinence Stable weight No family history of IBD or celiac disease Normal CBC, ESR, celiac serologies, and stool studies Normal flexible sigmoidoscopy with biopsies Lactose-free diet did not help Gluten-free diet x2 months did not help FODMAP diet x2 months did not help Imodium helps diarrhea a little, but no help with urgency or lower abdominal pain Diphenoxylate-atropine caused fatigue and palpitations Rifaximin was suggested, but her insurance company would not approve it 1. Appeal insurance company decision on rifaximin denial 2. Prescribe cholestyramine 1 g QD 3. Prescribe alosetron 0.5 mg QD 4. Prescribe alosetron 1 mg BID 5. Prescribe a SSRI 11
Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care
Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care February 7, 2013 Fort Lauderdale, Florida Educational Partner: Session 4: Under Pressure: The Need to Expedite IBS Diagnosis
More informationUnder Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care
Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care June 23, 2012 New York, New York Educational Partner: CME Incite, LLC Session 4: Under Pressure: The Need to Expedite IBS
More informationDigesting the Facts in IBS: From Early Diagnosis to Effective Treatment Options
Digesting the Facts in IBS: From Early Diagnosis to Effective Treatment Options September 19, 213 Boston, Massachusetts Educational Partner: Session 3: Digesting the Facts in IBS: From Early Diagnosis
More informationWhat s the Latest? Rome III Criteria for IBS
Irritable Bowel lsyndrome: What s the Latest? American College of Gastroenterology Las Vegas, January 2014 Bi Brian E. Lacy, Ph.D., PhD M.D., MD FACG Professor of Medicine Geisel School of Medicine at
More informationManagement of Functional Bowel Disorders
Management of Functional Bowel Disorders Amy Foxx-Orenstein, DO, FACG, FACP Professor of Medicine Mayo Clinic Tucson Osteopathic Medical Foundation May 1, 2016 Objectives Review epidemiology and pathophysiology
More informationIrritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM
Irritable Bowel Syndrome Now George M. Logan, MD Friday, May 5, 2017 3:35 4:05 PM Dr. Logan indicated no potential conflict of interest to this presentation. He does not intend to discuss any unapproved/investigative
More informationDisorders in which symptoms cannot be explained by the presence of structural or tissue abnormalities Irritable bowel syndrome Functional heartburn Functional dyspepsia Functional constipation Functional
More informationDavid Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:
David Leff, DO AOMA 94 th Annual Convention April 13, 2016 Disclosure I have the following financial relationships to disclosure: Speaker s Bureau: Allergan Labs, Takeda Pharmaceutical, Valeant Pharmaceutical
More informationThe Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
More informationRome III Criteria for IBS. Irritable Bowel Syndrome: What s the Latest? IBS: What s the Latest? Distinguishing IBS-C from CC
Rome III Criteria for IBS Irritable Bowel Syndrome: What s the Latest? Tim Burke, DO Pacific Digestive Associates Clackamas, OR Recurrent abdominal pain or discomfort at least 3 days/month in the last
More informationXifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary
Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Lotronex (alosetron) a Indication For women with severe diarrheapredominant irritable
More informationCurrent and Emerging Pharmacological Treatments in Irritable Bowel Syndrome
Current and Emerging Pharmacological Treatments in Irritable Bowel Syndrome Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School What is the general
More informationWilliam D. Chey, MD Professor of Medicine University of Michigan
Evidence-based Treatment Strategies for IBS William D. Chey, MD Professor of Medicine University of Michigan Rome III criteria for IBS Recurrent abdominal pain or discomfort at least 3 days / month in
More informationIrritable Bowel Syndrome. Paul Sheykhzadeh, DO, FACG Digestive Health Associates Reno, NV NAPNA Symposium March 5, 2016
Irritable Bowel Syndrome Paul Sheykhzadeh, DO, FACG Digestive Health Associates Reno, NV NAPNA Symposium March 5, 2016 Definition of Irritable Bowel Syndrome (IBS) Rome III Criteria Recurrent abdominal
More information4) Irritable Bowel Syndrome - Dr. Shaikhani. Epidemiology. Pathophysiology. Burden. Diagnosis
4) Irritable Bowel Syndrome - Dr. Shaikhani Epidemiology A common disorder, with a 7% prevalence. Women are 1.5 times more likely to be affected than men, most commonly between ages 20-40 years. Onset
More informationAdvancing gastroenterology, improving patient care
American College of Gastroenterology Advancing gastroenterology, improving patient care Note to Visitors: A fully updated ACG Systematic Review on the Management of Chronic Idiopathic Constipation and
More informationIBS Irritable Bowel syndrome Therapeutics II PHCL 430
Salman Bin AbdulAziz University College Of Pharmacy IBS Irritable Bowel syndrome Therapeutics II PHCL 430 Email:- ahmedadel.pharmd@gmail.com Ahmed A AlAmer PharmD R.S is 32-year-old woman experiences intermittent
More informationPresenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018
Presenter Irritable Bowel Syndrome Current evidence for diagnosis & management Julie Daniels DNP, CNM Assistant Professor Course Coordinator of Primary Care of Women Faculty at Frontier Nursing University
More informationChronic Abdominal Pain. Dr. Robert B. Smith Tupelo Digestive Health Specialists August 26, 2016
Chronic Abdominal Pain Dr. Robert B. Smith Tupelo Digestive Health Specialists August 26, 2016 Disclosures Speaker Bureau for Allergan Pharmaceuticals Abdominal Pain - Definitions Acute occurring for several
More informationIs one of the most common chronic disorders. causing patients to seek medical treatment.
ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing
More informationFunctional Dyspepsia
Functional Dyspepsia American College of Gastroenterology Boston Massachusetts, June 2015 Brian E. Lacy, PhD, MD, FACG Professor of Medicine Geisel School of Medicine at Dartmouth Chief, Section of Gastroenterology
More informationSESSION 5 2:30pm 3:45pm
SESSION 5 2:3pm 3:45pm Optimizing the Diagnosis, Treatment, and Management of Irritable Bowel Syndrome SPEAKERS Richard J. Saad, MD, MS Spencer Dorn, MD, MPH, MHA Presenter Disclosure Information The following
More informationIrritable Bowel Syndrome. Mustafa Giaffer March 2017
Irritable Bowel Syndrome Mustafa Giaffer March 2017 Introduction First described in 1771. 50% of patients present
More informationDiagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider
Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider Elizabeth Coss, MD General Gastroenterologist Audie Murphy Veterans Hospital UT Health This presentation does not
More informationPharmacotherapy for IBS
Pharmacotherapy for IBS Brooks D. Cash, M.D., FACG Chief, Gastroenterology Professor of Medicine University of South Alabama Director, GI Physiology, USA Medical Center Mobile, AL Disclosures I have served
More informationIBS - Definition. Chronic functional disorder of GI generally characterized by:
IBS - Definition Chronic functional disorder of GI generally characterized by: 3500 3000 No. of Publications 2500 2000 1500 1000 Irritable Bowel syndrome Irritable Bowel Syndrome 500 0 1968-1977 1978-1987
More informationPrimary Management of Irritable Bowel Syndrome
Primary Management of Irritable Bowel Syndrome Jasmine Zia, MD Acting Instructor, Division of Gastroenterology Current Concepts in Drug Therapy CME Course April 23, 2015 Irritable Bowel Syndrome (IBS)
More informationBloating, Flatulence, and
A 45-Year-Old Man With Recurrent Abdominal Pain, Bloating, Flatulence, and Intermittent Loose Stools Anthony J. Lembo, MD Associate Professor of Medicine Harvard Medical School Director, GI Motility Laboratory
More informationIrritable Bowel Syndrome
68 TH ANNUAL MCGILL REFRESHER COURSE FOR FAMILY PHYSICIANS 2017 Irritable Bowel Syndrome Gad Friedman, MDCM, FRCPC Jewish General Hospital DISCLOSURES I have no disclosures LEARNING OBJECTIVES 1. Review
More informationIRRITABLE BOWEL SYNDROME
DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) 415 14 TH ST. NW. CALGARY AB T2N2A1 PHONE (403) 270-9555 FAX (403) 270-7479 IRRITABLE BOWEL SYNDROME DEFINITION: *FUNCTIONAL GASTROINTESTINAL DISORDER CHARACTERIZED
More informationWhy does my stomach hurt? Exploring irritable bowel syndrome
Why does my stomach hurt? Exploring irritable bowel syndrome By Flavio M. Habal, MD, PhD, FRCPC Case In this article: 1. What is IBS? A 45-year-old female is referred to your office with recurrent 2. How
More informationStatement of Sponsorship and Support
Case Studies in the Practical Evaluation and Management of Irritable Bowel Syndrome with Diarrhea Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine
More informationIrritable Bowel Syndrome: Current and Emerging Treatment Options
Irritable Bowel Syndrome: Current and Emerging Treatment Options Lauren Peyton, PharmD, CDE; and Joy Greene, PharmD INTRODUCTION Irritable bowel syndrome (IBS), one of the most prevalent functional gastrointestinal
More informationEvolving Therapy in Irritable Bowel Syndrome (IBS)
Evolving Therapy in Irritable Bowel Syndrome (IBS) Dr. Syed Mohammad Arif MBBS, FCPS (Medicine), MD (Gastro) Associate Professor Department of Medicine Dhaka Medical College A good set of bowels is worth
More informationInflammatory or Irritable? (the bowel, not the speaker)
South GP CME Edgar Centre, Dunedin August 2014 Inflammatory or Irritable? (the bowel, not the speaker) Dr Jason Hill MBChB FRACP FRCP Edin Department of Gastroenterology, Southern DHB Dunedin School Of
More informationCurrent Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation
Current Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation Anthony Lembo, M.D. Associate Professor of Medicine Harvard Medical School Director, GI Motility Center Beth
More informationEmerging Treatments for IBS-C and Clinical Trial Endpoints
Emerging Treatments for IBS-C and Clinical Trial Endpoints Lin Chang, M.D. Oppenheimer Family Center for Neurobiology of Stress David Geffen School of Medicine at UCLA Learning Objectives Describe current
More informationDisclosures. 4 th Annual Digestive Disease IBS: New Management Approaches. Early description of symptoms defining IBS 1849 W Cumming.
4 th Annual Digestive Disease IBS: New Management Approaches Disclosures Consultant Alkermes, Allergan, Forest, Ironwood, Prometheus, Salix Anthony Lembo, M.D. Beth Israel Deaconess Medical Center Harvard
More informationState of the Art: Management of Irritable Bowel Syndrome
ACG/FGS Annual Spring Symposium March 16-18, 2018 Bonita Springs, FL State of the Art: Management of Irritable Bowel Syndrome William D. Chey, MD Professor of Medicine University of Michigan IBS: Rome
More informationROME IV CRITERIA FOR IBS
PRACTICAL CONSIDERATIONS IN THE MANAGEMENT OF IBS BRENDA HORWITZ MD PROFESSOR OF CLINICAL MEDICINE LEWIS KATZ SCHOOL OF MEDICINE AND TEMPLE UNIVERSITY HEALTH SCIENCES CENTER OR THINGS I ALWAYS WANTED TO
More informationIrritable bowel syndrome (IBS) is a chronic, potentially disabling
Evidence-Based Management of Irritable Bowel Syndrome With Diarrhea Mark Pimentel, MD Irritable bowel syndrome (IBS) is a chronic, potentially disabling disorder of the gastrointestinal (GI) tract with
More informationClinical Policy: Alosetron (Lotronex) Reference Number: CP.CPA.65 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal
Clinical Policy: (Lotronex) Reference Number: CP.CPA.65 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationSlide #43. Functional Disorders - An Update 11/8/ MA ACP Annual Scientific Meeting. Functional Disorders: An Update
Functional Disorders: An Update Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Disclosure of Financial Relationships Anthony
More informationPELVIC PAIN : Gastroenterological Conditions
PELVIC PAIN : Gastroenterological Conditions Departman Tarih Prof. A. Melih OZEL, MD Department of Gastroenterology Anadolu Medical Center Hospital Gebze Kocaeli - TURKEY Presentation plan 15 min. Introduction
More informationSlide #43. Disclosure of Financial Relationships. IBS: Is it in Your Head or Gut? Anthony Lembo, M.D. Associate Professor of Medicine
Disclosure of Financial Relationships : Is it in Your Head or Gut? Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Anthony Lembo,
More informationIrritable Bowel Syndrome. Kimberly Persley, MD Texas Digestive Disease Consultants NPPA Course 2015
Irritable Bowel Syndrome Kimberly Persley, MD Texas Digestive Disease Consultants NPPA Course 2015 Irritable Bowel Syndrome Bowels Patients NP/PA Irritable Employers Family Physicians Irritable Bowel Syndrome
More informationPsycho-pharmacologic Therapy. Objectives
Psycho-pharmacologic Therapy for Functional Bowel Disorders John J. Hutchings, M.D. Assistant Professor of Medicine and Psychiatry Louisiana i State t University it School of Medicine i Department of Medicine
More informationIrritable bowel syndrome: An overview of diagnosis and pharmacologic treatment
REVIEW KEVIN W. OLDEN, MD Associate Professor of Medicine, Division of Gastroenterology, Mayo Clinic Scottsdale, Scottsdale, Ariz. Irritable bowel syndrome: An overview of diagnosis and pharmacologic treatment
More informationImproving Primary Care Management of IBS D through Early Diagnosis and Personalized Treatment
Improving Primary Care Management of IBS D through Early Diagnosis and Personalized Treatment Provided by Integrity Continuing Education, Inc. Supported by an educational grant from Salix Pharmaceuticals,
More informationIrritable Bowel Syndrome and Chronic Constipation. Treatment of IBS. Susan Lucak, M.D. Columbia University Medical Center
Ti tl e s l i d e - p a rt 1 Irritable Bowel Syndrome and Chronic Constipation Susan Lucak, M.D. Columbia University Medical Center Treatment of IBS Abdominal pain / discomfort Antispasmodics Antidepressants
More informationCHRONIC DIARRHEA DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) DEFINITION: *LOOSE, WATERY STOOLS *MORE THAN 3 TIMES A DAY *FOR MORE THAN 4 WEEKS
DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) 415 14 TH ST. NW. CALGARY AB T2N2A1 PHONE (403) 270-9555 FAX (403) 270-7479 CHRONIC DIARRHEA DEFINITION: *LOOSE, WATERY STOOLS *MORE THAN 3 TIMES A DAY *FOR MORE
More information10/1/2016. Kimberly Kearns, MS, APN, ANP-BC Mary Davitt, MS, PMHNP-BC Rachel Richardson, RD. Kimberly Kearns, APN. Mary Davitt, PMHNP.
Kimberly Kearns, MS, APN, ANP-BC Mary Davitt, MS, PMHNP-BC Rachel Richardson, RD Kimberly Kearns, APN Speakers Bureau: Medtronic Salix Pharmaceuticals Takeda Pharmaceuticals Mary Davitt, PMHNP None Rachel
More informationIBS current status Peter Laszlo Lakatos
IBS current status Peter Laszlo Lakatos Semmelweis University 1st Department of Medicine Functional gastrointestinal disorders Chronic or fluctuating functional gastrointestinal symptoms that can not be
More informationIrritable Bowel Syndrome
Irritable Bowel Syndrome Functional gastrointestinal disorders Definition A variable combination of chronic or recurrent gastrointestinal symptoms (attributed to the pharynx, esophagus, stomach, biliary
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lotronex) Reference Number: CP.PMN.153 Effective Date: 11.16.16 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationPELVIC PAIN : Gastroenterological Conditions
PELVIC PAIN : Gastroenterological Conditions Departman Tarih Prof. A. Melih OZEL, MD Department of Gastroenterology Anadolu Medical Center Hospital Gebze Kocaeli - TURKEY Presentation plan 15 min. Introduction
More informationWhat is Irritable Bowel Syndrome (IBS)?
What is Irritable Bowel Syndrome (IBS)? Irritable bowel syndrome (IBS) is a health issue found in your intestines (gut). IBS can cause symptoms such as: Belly pain. Cramping. Gas. Bloating (or swelling)
More informationWilliam D Chey, 1 Anthony J Lembo, 2 James A Phillips, 3 David P Rosenbaum 4
Efficacy and safety of tenapanor in patients with constipationpredominant irritable bowel syndrome: a 12-week, double-blind, placebocontrolled, randomized phase 2b trial William D Chey, 1 Anthony J Lembo,
More informationDiagnosis and Treatment of Irritable Bowel Syndrome
Special Issue Diagnosis and Treatment of Irritable Bowel Syndrome Myung Gyu Choi, M.D. Department of Internal Medicine The Catholic University of Korea, College of Medicine Kangnam St. Mary's Hospital
More informationDo Probiotics Provide Adequate Relief From Overall Symptoms, Including Abdominal Pain and Bloating, in Adults With Irritable Bowel Syndrome?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Do Probiotics Provide Adequate Relief
More informationIBS: Updates on Diagnostics and Therapeutics for the Primary Practitioner
Rome IV: Diagnostic Criteria* IBS: Updates on Diagnostics and Therapeutics for the Primary Practitioner Darren M. Brenner, MD, AGAF Associate Professor of Medicine and Surgery Director Northwestern Functional
More informationFUNCTIONAL DISORDERS TREATMENT ADVANCES. Dr. Adriana Lazarescu MD FRCPC Director GI Motility Lab, Edmonton Associate Professor University of Alberta
FUNCTIONAL DISORDERS TREATMENT ADVANCES Dr. Adriana Lazarescu MD FRCPC Director GI Motility Lab, Edmonton Associate Professor University of Alberta Name: Dr. Adriana Lazarescu Conflict of Interest Disclosure
More informationDr. Melvyn Letier Constantiaberg Mediclinic October 2016
Dr. Melvyn Letier Constantiaberg Mediclinic October 2016 This presentation will enable you to: Understand the pathophysiology of IBS Recognize the clinical manifestations of IBS Make a confident diagnosis
More informationIBS. Dan Carter, M.D. Institute of Gastroenterology Sheba medical center
IBS Dan Carter, M.D. Institute of Gastroenterology Sheba medical center Epidemiology Irritable bowel syndrome is a common functional gastrointestinal disorder that manifests as abdominal pain or discomfort
More informationIBS CLOSED REFERRAL STATUS: Dear Dr.,
Name: PHN/ULI: DOB: RHRN: RefMD: Dr. RefMD Fax: RefDate: Date Today: CONFIRMATION: TRIAGE CATEGORY: REFERRAL STATUS: Dear Dr., Referral Received Enhanced Primary Care Pathway CLOSED IBS The clinical and
More informationNew Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome
New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome Soojong Hong Chae, MD Clinical Assistant Professor Digestive Diseases and Nutrition University of South Florida ROME III Functional dyspepsia
More informationDisclosures. Objectives. Pre-Test Question 1. Pre-Test Question 2. Pre-Test Question 3 9/23/2016
Disclosures Beating the Bowel Blues: An Update on the Treatment of Irritable Bowel Syndrome Matthew Nelson, PharmDBCPS, Roosevelt University College of Pharmacy Matthew Nelson declares no conflicts of
More informationAn Evidence-based Approach to Irritable Bowel Syndrome. Robert Baldor, MD, FAAFP
An Evidence-based Approach to Irritable Bowel Syndrome Robert Baldor, MD, FAAFP Robert Baldor, MD, FAAFP Professor and Vice Chair, Department of Family Medicine and Community Health/Director, Community-Based
More informationIBS-D: The Role of Pathophysiology in Assessment and Treatment ReachMD Page 1 of 7
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationIBS: overview and assessment of pain outcomes and implications for inclusion criteria
IBS: overview and assessment of pain outcomes and implications for inclusion criteria William D. Chey, MD Professor of Medicine University of Michigan What is the Irritable Bowel Syndrome Symptom based
More informationSession 3: The Fast Track: Improving the Management of Chronic Constipation and IBS-C in the Primary Care Setting
Session 3: The Fast Track: Improving the Management of Chronic Constipation and IBS-C in the Primary Care Setting Learning Objectives List the criteria for the diagnosis of chronic constipation and irritable
More informationUnderstanding and Managing IBS and CIC in the Primary Care Setting
May 2018 Volume 14, Issue 5, Supplement 3 Understanding and Managing IBS and CIC in the Primary Care Setting Brooks D. Cash, MD Chief of the Division of Gastroenterology, Hepatology, and Nutrition University
More informationEffects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
Alimentary Pharmacology and Therapeutics Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation L. Chang*, W. D. Chey, D.
More informationTreatment of IBS - Diet or Drugs?
Treatment of IBS - Diet or Drugs? Brooks D. Cash, MD, FACG Professor of Medicine University of South Alabama Director, GI Physiology, USA Medical Center Mobile, AL Learning objectives Review the evolving
More informationTenapanor for irritable bowel syndrome with constipation
NIHR Innovation Observatory Evidence Briefing: February 2018 Tenapanor for irritable bowel syndrome with constipation NIHRIO (HSRIC) ID: 6704 NICE ID: 9736 LAY SUMMARY Irritable bowel syndrome with constipation
More informationIBS-D: What to Do When Typical Treatment Methods Fail
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationJointly sponsored by Purdue University College of Pharmacy and the Gi Health Foundation. This activity is supported by Salix Pharmaceuticals.
Accredited by Jointly sponsored by Purdue University College of Pharmacy and the Gi Health Foundation. This activity is supported by Salix Pharmaceuticals. Mark Pimentel, MD Cedars-Sinai Medical Center
More informationNicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia. Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Nicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia
More informationCHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University
CHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University 1 Definition of FGID Chronic and recurrent symptoms of the gastrointestinal
More informationIrritable Bowel Syndrome and Chronic Constipation
Title slide - part 1 Irritable Bowel Syndrome and Chronic Constipation IBS - Physiologic Research Stress affects GI function Meals Pain / motility Time Line of Physiologic Research in IBS Pain sensitivit
More informationIrritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS) Dr Rex J Polson 17 th January 2018 Overview Description of the condition Discussion of symptoms and investigations that may be required Discussion of management and treatment
More informationObjectives. Pain Types Brief Review. Referred Pain. Chronic/Recurrent Abdominal Pain 1/12/2017. I have no conflicts of interest to disclose
Joshua D Noe, MD Associate Professor of Pediatric Gastroenterology Hepatology and Nutrition Medical College of Wisconsin I have no conflicts of interest to disclose Objectives Differentiate functional
More information5 Things to Know About Irritable Bowel Syndrome
5 Things to Know About Irritable Bowel Syndrome Mike Kolber MD, CCFP, MSc PEIP 2017 Faculty/Presenter Disclosure Presenter: Mike Kolber Relationships that may introduce potential bias and/or conflict of
More informationThe long-term impact of the low-fodmap diet for management of irritable bowel syndrome. Dr Miranda Lomer RD.
The long-term impact of the low-fodmap diet for management of irritable bowel syndrome Dr Miranda Lomer RD Email: miranda.lomer@kcl.ac.uk What is IBS - ROME IV Criteria A functional bowel disorder in which
More informationLow FODMAP Dietary Approach For FGD/IBS. Our Experience. Charlotte McCamphill 19 th February 2015
Low FODMAP Dietary Approach For FGD/IBS Our Experience Charlotte McCamphill 19 th February 2015 CONTENTS What Is IBS What are FODMAPs Service Provision Audit Results Future Work WHAT IS IBS The Rome III
More informationWilliam Chey, MD University of Michigan Ann Arbor, MI
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA William Chey, MD University of Michigan Ann Arbor, MI Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Accredited by Jointly
More informationWhat s New in IBS with Diarrhea. Dr. Geoffrey K. Turnbull, MD April 6, 2018.
What s New in IBS with Diarrhea Dr. Geoffrey K. Turnbull, MD April 6, 2018. Objectives To learn how to diagnose IBS with particular emphasis on patients who have diarrhea predominantly. Review management
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationAn Evidence-based Approach to Dietary Treatment of Irritable Bowel Syndrome
An Evidence-based Approach to Dietary Treatment of Irritable Bowel Syndrome American College of Gastroenterology August 2014, Indianapolis Brian E. Lacy, Ph.D., M.D. Professor of Medicine, Geisel School
More informationIBS and Functional GI Disorders (FGIDs)
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/gi-insights/ibs-and-functional-gi-disorders-fgids/7424/
More informationIs Gut-Directed Hypnotherapy An Effective Treatment For Refractory IBS?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is Gut-Directed Hypnotherapy An Effective
More informationFood Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence
Food Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence Maria Vazquez Roque, MD, MSc Assistant Professor Gastroenterology and Hepatology 2010 MFMER slide-1 Objectives Gluten-free
More informationอภ ชาต แสงจ นทร ภาคว ชาอาย รศาสตร คณะแพทย ศาสตร มหาว ทยาล ยขอนแก น
อภ ชาต แสงจ นทร ภาคว ชาอาย รศาสตร คณะแพทย ศาสตร มหาว ทยาล ยขอนแก น Functional bowel disorder characterized by abdominal pain or discomfort and altered bowel habits in the absence of detectable structural
More informationIrritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice
Review Article Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice United European Gastroenterology Journal 2017, Vol. 5(6) 773 788! Author(s) 2016 Reprints
More informationAddendum to NICE guideline CG61, Irritable bowel syndrome in adults
National Institute for Health and Care Excellence Draft for consultation Addendum to NICE guideline CG61, Irritable bowel syndrome in adults Diagnosis and management of irritable bowel syndrome in primary
More informationIntestinal, non-intestinal, and extra-digestive response to linaclotide in patients with IBS-C: results at Week 4 predict sustained response
Intestinal, non-intestinal, and extra-digestive response to linaclotide in patients with IBS-C: results at Week 4 predict sustained response Blanca Serrano, 1 Silvia Delgado-Aros, 2 Fermín Mearin, 3 Constanza
More informationElderly Man With Chronic Constipation
Elderly Man With Chronic Constipation Linda Nguyen, MD Director, Neurogastroenterology and Motility Clinical Assistant Professor Stanford University Overview Normal bowel function Defining Constipation:
More informationOutline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments
Chronic Dyspepsia Eamonn M M Quigley MD FRCP FACP MACG FRCPI Lynda K and David M Underwood Center for Digestive Disorders Houston Methodist Hospital Houston, Texas Outline Definition (s) Epidemiology Pathophysiology
More informationIrritable Bowel Syndrome
CLINICAL FEATURE Irritable Bowel Syndrome An evidence-based review of new diagnostic criteria and treatment recommendations. ABSTRACT: Irritable bowel syndrome (IBS) is a common, chronic gastrointestinal
More informationRefractory IBS-D: An Evidence-Based Approach to Therapy
Refractory IBS-D: An Evidence-Based Approach to Therapy Darren M. Brenner, MD, AGAF Associate Professor of Medicine and Surgery Director, Northwestern Neurogastromotility, Functional, and Integrated Bowel
More information